Celularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 52.3% in September

Celularity, Inc. (NASDAQ:CELU) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 391,276 shares, a decline of 52.3% from the September 15th total of 821,020 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average trading volume of 154,929 shares, the days-to-cover ratio is currently 2.5 days.

Celularity Stock Performance

Shares of CELU stock traded up $0.01 during trading on Thursday, hitting $1.32. 19,590 shares of the company were exchanged, compared to its average volume of 1,356,692. The business’s 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.03. Celularity has a twelve month low of $0.56 and a twelve month high of $2.55. The firm has a market capitalization of $42.87 million, a price-to-earnings ratio of -0.49 and a beta of 0.77.

Celularity (NASDAQ:CELU) last issued its earnings results on Tuesday, September 29th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $3.85 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in Celularity, Inc. (NASDAQ:CELU) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest holding. C V Starr & Co. Inc. owned 2.64% of Celularity at the end of the most recent reporting period. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.